IL1B and mevalonic aciduria: Therapeutic tools for MKD are numerous and differently effective, as non-steroidal anti-inflammatory drugs or biological agents targeting IL-1, such as anakinra (also given ‘on-demand’) and canakinumab have been used; hematopoietic stem cell transplantation has been addressed to the most severe patients or in those with mevalonic aciduria [49].